| Summary: | 碩士 === 國立屏東科技大學 === 獸醫學系所 === 100 === Avian reovirus (ARV) has been reported in causing stunting, malabsorption, arthritis and respiratory syndromes in poultrys. A Taiwanese isolate ( V511) of ARV was serially passaged and well adapted BHK-21 cell for 50 generations. The ARV at 10th, 20th, 30th, 40th and 50th passage levels were massively produced and stocked, cytopathic effect scored, virus population titrated, variation on the nucleotide of sigma C (σC ) geme evaluated as the references for the live attenuated or inactivated ARV vaccine development. Safety and protectivity of the ARV-V511 vaccine at each 10th passage levels were individually conducted in chickens in combination with the commercial available ARV vaccines in Taiwan. A passage level of V511 with the best safety and protectivity in chickens will be selected for the development of live or inactivated ARV vaccine. ARV-V511 isolate cultivated in BHK-21 cell to 50 passages, were found with gradually enhencing of its pathogenicity to the BHK-21 cell, also with the to virus population raised from 101 to 108.5 TCID50/mL. BHK-21 comes be 100％ used for V511 strain vaccine virus production. Groups of leghorn chicken subcutaneously vaccinated with the V511 inactivated or live vaccine at variant passage level or titer provided good safety at 6 weeks post vaccination. All the inactivated vaccine immunized groups even gave good ARV ELISA antibody response and 100% protectivity against the challenge. Even in the group immunized with the vaccine only containing of 25% of the original suspension. However only the group the chickens immunized with the V511-30th and 50th live vaccine containing 104 to105 TCID50 ARV per dose provided good ELISA antibody response and 100% protection agsinst the challenge. Adaption of ARV-V511 strain cultivated in BHK-21 cell provided some aspect in the development of ARV inactivated or live vaccine for using in chickens.
|
|---|
